[Adjuvant BCG immunotherapy for breast cancer (T1N0M0, T2N0M0)].
The present study was performed to evaluate the effect of BCG immunotherapy for breast cancer (T1n0M0, T2n0M0) in nonrandomized series. During a 5-year follow-up study, patients in the BCG-treated group suffered neither recurrence nor death, while the historical control group had 6 cases of recurrence and 5 cases of disease death. As seen in our series, we concluded that breast cancer patients should be advised to accept adjuvant BCG immunotherapy after mastectomy.
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D005260:Female; D006801:Humans; D008408:Mastectomy; D011184:Postoperative Period
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine